Spectrum Pharma (SPPI) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Spectrum Pharmaceuticals Reports First Quarter 2017 Financial Results and Pipeline Update
May 2, 2017 4:02 PM EDTROLONTIS (eflapegrastim): Phase 3 ADVANCE Pivotal study: Number of evaluable patients reduced to 400 from 580, per an amended Special Protocol Assessment (SPA) received from the FDA. ADVANCE study is 75% enrolled and the Company expects to complete enrollment in the second half of this year. To strengthen the regulatory package in the U.S. and Europe, the Company has initiated an international 218-patient RECOVER study and first patient enrollment is imminent. The Company continues to expect to file a BLA next year.... More
